RNS REACH |6 JANUARY 2026
ImmuPharma PLC
("ImmuPharma" or the "Company")
IMMUPHARMA AT JP MORGAN CONFERENCE & BIOTECH SHOWCASE™
12-14 January 2026 | San Francisco
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO, will be attending both the JP Morgan Conference and the Biotech Showcase from 12-14 January 2026, in San Francisco, USA.
The JP Morgan conference and Biotech Showcase are annual premier partnering events, designed to provide biotechnology companies with the opportunity to present to and connect with global Biopharma companies and investors.
End
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
About JP Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference 2026 is the industry's premier investment symposium. It draws over 8,000 attendees including pharma/biotech executives, investors, startups, analysts, and policymakers for strategic discussions and dealmaking.
About Biotech Showcase
Biotech Showcase in San Francisco is an investor‑focused partnering conference held each January alongside JP Morgan Healthcare Conference week. It is designed mainly for private and micro‑ to mid‑cap biotech companies to meet global investors and pharma executives.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.